Medically unexplained symptoms (MUS) is the term used to address disorders where physical symptoms have no medical explanation. Currently, most patients with general MUS fit the diagnostic criteria for ‘undifferentiated somatoform disorder’ (DSM-IV, 300.82; ICD-10, F45.1). According to data on healthcare utilisation, 15–30% of consultations in primary and secondary care concern patients with MUS (e.g. chronic pain, fatigue, headache, dizziness or functional somatoform disorder), resulting in significantly higher healthcare utilisation in secondary care and high associated costs. A number of models for engaging patients with MUS in primary care have been used, but those are limited by poor acceptability among general practitioners (GPs) and patients alike. Specialist secondary mental healthcare services with their focus on severe mental illness rarely make provisions for these patients. Systematic studies suggest that these patients have high psychiatric comorbidity, severe functional impairment and a poor quality of life; typically patients with MUS see themselves as physically ill.

Smith & Dwamena emphasised the lack of evidence-based treatment guidelines for primary care clinicians who care for most patients with MUS. An increase in the number and breadth of therapies for this patient group is therefore desirable. Previous research has demonstrated that a significant improvement in therapeutic engagement and symptom reduction can be achieved while offering the symptom-focused approach of a body-oriented psychological therapy (BOPT) for specific psychosomatic disorders. This evaluation aims to:

1. analyse the clinical characteristics and service utilisation of patients referred with MUS;
2. study the impact of somatic and depressive symptoms on patient function;
3. explore service use and distress levels of patients with somatoform disorder both before and after BOPT.

**Method**

A cross-sectional analysis was conducted on data obtained from patients referred consecutively to a specialist MUS clinic in the London borough of Newham (70% of the population are derived from minority ethnic groups; sixth most deprived borough in the country). The clinic was developed following a consultation process involving the GP mental health leads and used existing secondary care resources only. It aimed to provide an assessment and consultation service for patients with a variety of different MUS (referral criteria in Box 1), who would otherwise have no access to a local primary or secondary healthcare service.
specific to their needs. Clinical interviews/assessments were carried out by two trained psychiatrists over a period of 24 months; primary/secondary diagnoses and symptom severity were established while applying ICD-10 criteria and using a range of structured assessment tools.

Patients with an established diagnosis of somatoform disorder were offered body-oriented psychotherapy. The BOPT approach combines verbal with non-verbal strategies with a focus towards emotional processing/expressiveness, movement behaviour and body/self-perception; it is regarded as advantageous for patients with MUS since the bodily complaints remain the focus of therapy. The therapy is not aiming to ‘eradicate’ symptoms but to work with and through the body in respect of mental distress associated with the symptoms. The interventions do not directly address psychological processes associated with bodily experiences, aiming at a more subtle integration of the somatic and psychological aspects.

The baseline analysis included all 147 referrals from the first 2 years of the clinic (mean age 41.3 years, s.d. = 10.9; 32.6% male, 67.4% female). Patients were grouped for analysis according to their ethnicity (African-Caribbean: 32.6% male, 67.4% female). Patients were grouped for the first 2 years of the clinic (mean age 41.3 years, s.d. = 10.9; primary/secondary diagnoses and symptom severity were established while applying ICD-10 criteria and using a range of structured assessment tools.

Patients who presented persistently with physical symptoms, often persistent requests for medical investigations, in spite of repeated negative findings (where no physical basis for the symptoms was established/no evidence for disturbance of structure or function of the physical system/organ concerned). The clinic provides specialist assessments for the following group of patients (all of whom must have a score of \( \geq 10 \) on the Patient Health Questionnaire (PHQ-15)) somatic symptom severity screening scale or one very prominent medically unexplained symptom (e.g. pain):

(a) patients who frequently present in primary or secondary care with medically unexplained somatic sensations
(b) patients with a suspected or established diagnosis of severe and enduring conversion or somatoform disorder
(c) patients with an established or suspected diagnosis of body image disorder
(d) patients with a suspected or established diagnosis of anxiety and/or depressive disorder, who mainly present with predominant somatic symptoms.

Results

Referrals

A total of 147 patients were referred to the clinic. Most referrals came from GPs (n = 65, 44.2%) and fellow mental health professionals (n = 59, 40.1%). The remaining 23 patients were referred by specialist medical services from the general hospital. There was a notable difference in referral rates across GP surgeries in the borough, with only half of practices making any referrals (mostly 1–3 patients per GP practice in total).

Somatic symptoms/complaints analysis

The most frequent presenting complaint was localised pain (e.g. headache, pain in legs or back; n = 44, 38.9%), followed by generalised pain (n = 31, 27.4%); 7 patients (6.2%) reported neurological symptoms (e.g. paralysis, loss of sensation). Only 13 patients (11.5%) reported psychological symptoms (such as feeling low, anxious) as their main presenting complaint (Fig. 1 presents most frequent complaints for two disorder groups, depressive and somatoform disorders).

Among patients with a current depressive episode, only 7 (18.4%) reported psychological symptoms (low mood) as their presenting complaint. Almost all patients presented with multiple physical complaints; 32% of females (n = 25) and 15% of males (n = 6) reported generalised pain. Asian patients reported generalised pain more frequently than all the other ethnic groups together as their main presenting complaint (37%). A significantly higher proportion of patients in the White group (23%) reported psychological symptoms as their presenting complaint (compared with only 3% for the rest of the cohort, Pearson’s \( \chi^2 = 7 \), d.f. = 1, \( P = 0.009 \)).

Analysis of diagnostic groups

The majority of patients assessed at the MUS clinic (n = 106 out of 113) received a diagnosis of mental disorder (Table 1); there was no significant between-group difference according to ethnicity. Nearly a third of patients (n = 30, 29%) fulfilled assessed with the: Hamilton Rating Scale for Depression (HRSD; with cut-off points of 15–19 for moderate, 20 or above for severe); Patient Health Questionnaire (PHQ-15); Global Assessment of Functioning (GAF); and Screening for Somatoform Symptoms-7 (SOMS-7).

Following the descriptive analysis of service utilisation and morbidity scores, further analysis was carried out to identify differences between diagnostic and ethnic groups in respect of somatic symptoms and other clinical characteristics. This was conducted with univariate analysis using student’s t-test or ANOVA for quantitative variables or \( \chi^2 \)-test for categorical variables. Predictive factors were assessed with variables entered into multiple logistic regressions with symptom scores or service utilisation as the dependant variable. Changes in symptom score and data on service utilisation for 3 months after the treatment with BOPT ended were analysed using paired t-tests. Statistical analysis used SPSS 17 for Windows. Analyses were only carried out if the missing data were less than 30% of the numbers.
criteria for a comorbid diagnosis, predominantly depressive disorder (n = 20) or anxiety disorder (n = 10). The majority of patients diagnosed with a current depressive episode (n = 26, 68.4%) did not have a recorded history of depression.

Impact of somatic and depressive symptoms on patient functioning

In the somatoform disorder group, HRSD and SOMS-7 scores were negatively correlated with GAF scores (Pearson's correlation $r = -0.68$, $P < 0.001$ and $r = -0.62$, $P < 0.001$ respectively). There was a positive correlation between HRSD and SOMS-7 total scores in this group ($r = -0.65$, $P < 0.01$). Entering HRSD and SOMS-7 scores along with age, gender, ethnicity, comorbidity and medication use into a multiple regression model, HRSD score was the only significant parameter associated with the level of function ($F = 11.2$, $t = -2.5$, $P < 0.05$). Similar associations were not observed in other diagnostic groups. In the depressive disorder group, only the HRSD scores were negatively correlated with the GAF score ($r = -0.4$, $P < 0.05$), but no correlation was found between the HRSD and SOMS-7 scores.

Service utilisation prior to referral to MUS clinic

GP surgery attendance

The mean number of attendances at a GP surgery in the previous year for the MUS cohort was 13.6 (s.d. = 10.5, range 0–45). Female patients (mean = 15.8 v. male patients; mean 9.6; $F = 6.2$, d.f. = 1, $P < 0.05$) and Asian patients (mean = 16.5 v. others; mean = 11.5; $F = 4.38$, d.f. = 1, $P < 0.05$) attended their GP practice significantly more often.

A&E attendance and referrals to other specialties

Mean number of attendances at the A&E department of the local general hospital during the 12 months prior to referral was 2.5 (s.d. = 3.5, range 0–16). There was no significant association between the number of A&E attendances and any other factors. The mean number of referrals to specialist services was 2.7 (s.d. = 2.4, range 0–12). Significantly more referrals were recorded for: females, individuals with medical history of physical disorder and those of White ethnicity. A significantly lower number of referrals to specialist services was recorded for Asian patients when compared with the sample as a whole.

Utilisation of MUS clinic service

Overall, 34 patients (23.1% of referrals) did not attend the initial assessment appointment at the clinic despite a number of attempts to contact them and the clinic operating a flexible appointment system. Attendance for assessment did not vary significantly among different ethnic groups. Those patients who did not attend the MUS clinic also had significantly lower attendance rates at their GP practice (but no higher A&E attendance rates or specialist referral rates) in the previous year: mean = 7.8, s.d. = 4.8 v. patients who did attend the MUS clinic, mean = 13.65, s.d. = 10.50; $F = 4.7$, d.f. = 1, $P < 0.05$.

There was no significant difference between patients attending/not attending in respect of age, gender, employment status, source of referral, presenting complaint, PHQ-15 scores, or with regard to a history of physical or mental disorder.

Outcomes following MUS clinic assessment

Following assessment at the MUS clinic, 41 patients (36.2%) with a diagnosis of somatoform disorder were referred to BOPT; 34 patients (30.1%) were referred to secondary care mental health services and 13 patients (11.5%) were referred for other forms of psychological therapy, mainly cognitive–behavioural therapy (CBT). Only 11 patients (9.8%) were immediately referred back to GPs with specific advice to improve the clinical management. Fourteen patients (12%) were identified as not suitable for the MUS clinic, mostly due to possible medical causes not having been ruled out or because of physical symptoms identified as resulting from a psychotic presentation (i.e. cenesthesias or somatic hallucinations). Pharmacological interventions were initiated in the clinic as follows: starting antidepressants ($n = 12$); optimising the dose of existing antidepressant treatment ($n = 13$); and changing antidepressants or other psychotropic drugs ($n = 10$).

BOPT group analysis

Out of the group of 41 patients identified with a primary diagnosis of somatoform disorder and referred for BOPT, only 12 (29.3%) participated in the assessment and treatment process (3 males (7.3%) and 9 females (22%)). The demographic and clinical characteristics of the group of patients undergoing BOPT did not differ significantly from those who did not participate. The mean age of participants was 43.5 years (s.d. = 6.2); distribution across ethnic groups was: Asian $n = 8$, White $n = 2$, African–Caribbean $n = 2$. Participants attended a mean of 11 out of 15 sessions offered (s.d = 5.2). Follow-up data were collected at 3 months after treatment for symptoms and functional scores. Data on
service utilisation were collected for the year following the end of BOPT. The PHQ-15 score indicated significant improvement for somatic complaints following treatment but there was no significant difference in depression scores. Service utilisation in the year following BOPT (A&E attendance and referrals to specialist services) reduced significantly and GP attendance figures showed a considerable trend towards reduction in service use. Outcomes for the BOPT group are summarised in Table 2.

**Discussion**

Factors influencing MUS liaison clinic service utilisation

The distribution of ethnic groups among patients who were referred to and attended the MUS clinic largely reflected the population statistics for the London borough of Newham. Asian patients presented more frequently with generalised pain than patients from other ethnic groups. Similar ethnic differences in expression of musculoskeletal pain have previously been reported in UK samples and this may be regarded as an unspecific but meaningful indicator for the prevalence of the somatoform syndrome in this group. This may also explain the discrepancy between the higher number of GP surgery visits and lower number of referrals to specialist services in the Asian group.

It is noteworthy that the majority of patients assessed in the liaison clinic had a previously undetected mental disorder. More than a third of patients assessed for MUS had a significant depressive disorder (moderate to high HRSD scores) with somatic symptoms in the context of this primary diagnosis. This finding supports the inclusion of somatisation syndromes in depressive and anxiety disorders as referral criteria for MUS clinics, since patients with depression and anxiety may only present with somatic symptoms. It also emphasises the need for better recognition of depression in primary care as highlighted in National Institute for Health and Care Excellence guidelines.

Pain localised to a particular area of the body was common in all diagnostic groups. The levels of somatic symptom severity and functional impairment were

---

### Table 1 Diagnostic group characteristics

| Comorbidity | All patients |
|-------------|--------------|
| n = 30      |              |
| Depression disorder n = 12 (26%), anxiety disorder n = 5 (11%) | |
| n (%)       | 106          |
| Age, years: mean (s.d.) | 41 (9.1) |
| Gender, n (%) | Male 34 (32), female 72 (68) |
| PHQ-15, mean (s.d.) | 17.6 (6.7) |
| HRSD total, mean (s.d.) | 18.4 (8.4) |
| SOMS-7 total, mean (s.d.) | 52.7 (26.3) |
| GAF, mean (s.d.) | 54.3 (13.4) |

### Table 2 Body-oriented psychological therapy group outcomes

| Outcome measures | Before treatment Mean (s.d.) | 3 months post-treatment Mean (s.d.) | Paired-sample t-test |
|------------------|-----------------------------|------------------------------------|---------------------|
| HRSD total       | 19 (7.7)                    | 18.2 (7.9)                         | t = 0.93, n.s.      |
| PHQ-15 total     | 17.7 (3.3)                  | 15.1 (4.9)                         | t = −2.2, P < 0.05 |
| GP attendance    | 17.8 (10)                   | 10.5 (7.8)                         | t = −2.0, n.s.      |
| Specialist referrals | 3.4 (2)                    | 1.2 (1.5)                          | t = −5.7, P < 0.01 |
| A&E attendance   | 2.5 (1.9)                   | 0.9 (0.7)                          | t = −2.8, P < 0.05 |

A&E, accident and emergency; GP, general practice; HRSD, Hamilton Rating Scale for Depression; PHQ-15, Patient Health Questionnaire; n.s., not significant.
The significant reduction in symptom levels and service use for the year after therapy.

Other psychotherapeutic models successfully utilised for the treatment of MUS, such as brief psychodynamic interpersonal therapy and mentalisation-based CBT, equally refer to concepts of developmentally or learning-based dysregulations of bodily self-experience and relationships. The BOPT model, however, offers a fundamentally different approach, connecting cognitive and emotional levels with bodily states through enactment and expressive movement exercises. This is done without explicitly relating to potentially underlying psychological conflicts or identifying and modifying dysfunctional automatic thoughts. Hereby patients are enabled “to make the breakthrough to a new level of understanding, without the requirements of verbalisation.”

This treatment modality adds another option to the available spectrum of psychotherapeutic approaches.

Take-up of BOPT was relatively low, with only 12 out of 41 patients referred participating. This may be partially due to patients adopting somatically dominated explanatory models and their reluctance to engage in any form of psychological therapy, and/or because the therapy was provided within mental healthcare premises. Otherwise, it was encouraging to see that the body-oriented approach was mainly taken up by patients from an ethnic minority background.

Strengths and limitations of the study

The study was conducted in a naturalistic setting as a service evaluation and the results are therefore mainly used for the assessment process, nearly a quarter did not attend the MUS clinic; their somatic symptom severity was comparable to those who attended, suggesting a high level of unmet need in this area. Those patients who attended, who frequently attended GP surgery appointments, accepted the specialist MUS clinic setting within mental health services well, whereas the findings suggest that a significant proportion of patients with MUS may only be engaged successfully in a collaborative and creative management process offered at primary care level. The specialist clinic served as nodal point of expert advice for appropriate pharmacological and psychological intervention for patients with MUS. It also facilitated access to secondary care mental health services where appropriate.

Association between depression and somatoform disorders and its implication

In the somatoform disorder group, the degree of depressive symptoms was the highest predictor for the overall level of patient function. This relationship held true even after controlling for comorbid clinical depressive episodes. This highlights the association of depressive symptoms with somatoform disorders, even at subsyndromal level. The small sample size of our cohort and methodological restrictions allow only for cautious interpretation, but the results confirm findings from previous studies regarding the close association between depression, anxiety and somatoform disorders and contribute to the renewed nosological discussion considering a significant overlap between them.

BOPT for MUS (somatoform disorder)

The results from the small sample of this pilot are in line with previous studies, indicating that BOPT is a promising intervention for patients with MUS, particularly those with undifferentiated somatoform pain disorder, who frequently attend primary care. There was an early reduction in the reporting of somatic symptom severity and also a significant reduction in service use for the year after therapy.

More specifically developed primary–secondary liaison services for patients with MUS problems are needed to improve the detection, recognition and adequate treatment of these patients and reduce the associated costs to healthcare systems. These services should include proactive identification (‘case finding’) elements and innovative models of engagement with patients within primary care settings (e.g. joint consultation model).

More research is needed to identify suitable service pathways and placement of service delivery, in a way that would provide better access to adequate care for all patients with MUS. The recently published Dutch multi-disciplinary guideline for MUS similarly emphasises the importance of a ‘disease-management based on risk profiles, providing stepped care and case management by the GP, supported by psychiatric consultation.’ For the UK, the development of innovative new treatments has been encouraged in the context of the expanded Improving Access to Psychological Therapies (IAPT) pathfinder programme for people with long-term conditions and/or MUS.

The significant reduction in symptom levels and service utilisation in the small BOPT group described here seems promising. This impact should be evaluated in an adequately
powered and larger controlled study aiming specifically to explore the benefits of BOPT for patients who otherwise do not engage in or do not respond to talking therapies. The new intervention could potentially translate into significant cost savings to the health service if this approach can demonstrate cost-effectiveness in larger trials.

About the authors
Frank Röhrich, MD, FRCPsyC is Consultant Psychiatrist and Clinical Director, East London NHS Foundation Trust, and Honorary Professor, University of Essex. Thomas Elanjithara, MRCPsyC is Locum Consultant Psychiatrist, Coventry and Warwickshire NHS Partnership Trust, and Honorary Research Associate, Institute of Psychiatry, London.

References
1. Hatcher S, Arroll B. Assessment and management of medically unexplained symptoms. BMJ 2008; 336: 1124–8.
2. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). APA, 1994.
3. World Health Organization. International Classification of Diseases, Tenth Edition (ICD-10). WHO, 2010.
4. Reid S, Wessely S, Crayford T, Hotopf M. Medically unexplained symptoms in frequent attenders of secondary health care: retrospective cohort study. BMJ 2001; 322: 767–9.
5. Smith RC, Dwamena FC. Classification and diagnosis of patients with medically unexplained symptoms. J Gen Intern Med 2007; 22: 685–91.
6. Burton C. Beyond somatisation: a review of the understanding and treatment of medically unexplained physical symptoms (MUPS). Br J Gen Pract 2003; 53: 231–5.
7. Reid S, Wessely S, Crayford T, Hotopf M. Frequent attendees with medically unexplained symptoms: service use and costs in secondary care. Br J Psychiatry 2002; 180: 248–53.
8. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical morbidity. Arch Gen Psychiatry 2005; 62: 903–10.
9. Hiller W, Fichter MM, Rief W. A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. J Psychosom Res 2003; 54: 369–80.
10. Morriss R, Gask L, Dowrick C, Dunn G, Peters S, Ring A, et al. Randomized trial of reattribution on psychosocial talk between doctors and patients with medically unexplained symptoms. Psychiat Med 2010; 40: 325–33.
11. Paterson C, Taylor RS, Griffiths P, Britton N, Rugg S, Bridges J, et al. Acupuncture for ‘frequent attenders’ with medically unexplained symptoms: a randomised controlled trial (CACTUS study). Br J Gen Pract 2011; 61: 295–305.
12. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003; 12: 34–43.
13. Duddu V, Husain N, Dickens C. Medically unexplained presentations and quality of life: a study of a predominantly South Asian primary care population in England. J Psychosom Res 2008; 65: 317–7.
14. Loew TH, Tritt K, Siegfried W, Bohmann H, Martus P, Hahn EG. Efficacy of ‘functional relaxation’ in comparison to terbutaline and a ‘placebo relaxation’ method in patients with acute asthma. A randomized, prospective, placebo-controlled, crossover experimental investigation. Psychother Psychosom 2001; 70: 151–7.
15. Lahmann C, Röhrich F, Sauer N, Noll-Hussong M, Ronel J, Henrich G, et al. Functional relaxation as complementary therapy in irritable bowel syndrome: a randomized, controlled clinical trial. J Altern Complement Med 2010; 16: 47–52.
16. Lahmann C, Nickel M, Schuster T, Sauer N, Ronel J, Noll-Hussong M, et al. Functional relaxation and guided imagery as complementary therapy in asthma: a randomized controlled clinical trial. Psychother Psychosom 2009; 78: 233–9.
17. Newham London Regeneration Planning and Property Directorate. Newham, London Local Economic Assessment 2010–2027. London Borough of Newham, 2010 (http://www.newham.info/Custom/LEA Demographics.pdf).
18. GlaxoWellcome. HRSID-21: The Hamilton Rating Scale for Depression. GlaxoWellcome, 1997 (http://healthnet.umm.edu/mhealth/HAMD.pdf).
19. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 258–66.
20. Jones SR, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654–9.
21. Rief W, Hiller W. A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics 2003; 44: 492–6.
22. Allison TR, Symmons DP, Brammah T, Haynes P, Rogers A, Roxby M, et al. Musculoskeletal pain is more generalised among people from ethnic minorities than among white people in Greater Manchester. Ann Rheum Dis 2002; 61: 151–6.
23. Simon GE, Von Korff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341: 1329–35.
24. Aguera L, Falide I, Cervilla JA, Diaz-Fernandez P, Mico JA. Medically unexplained pain complaints are associated with underlying unrecognized mood disorders in primary care. BMC Fam Pract 2010; 11: 17.
25. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults (Clinical Guideline CG90). NICE, 2009.
26. Lieb R, Meinlischmidt G, Araya R. Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: an update. Psychosom Med 2007; 69: 860–3.
27. Henningsen P, Zimmerman T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528–33.
28. Goldberg D. Should our major classifications of mental disorders be revised? Br J Psychiatry 2010; 196: 255–6.
29. Nickel M, Cangoze B, Bachler E, Muehlbacher N, Mueller-Rabe N, et al. Bioenergetic exercises in inpatient treatment of Turkish immigrants with chronic somatoform disorders: a randomized, controlled study. J Psychosom Res 2006; 61: 507–13.
30. Röhrich F. Body-oriented psychotherapy: the state of the art in international study of the relation between somatoform disorders and anxiety and depressive disorders: an update. Psychosom Med 2007; 69: 860–3.
31. Payne H, Stott D. Change in the moving bodymind: quantitative results from a pilot study on the use of the BodyMind approach (BMA) to psychotherapeutic group work with patients with medically unexplained symptoms (MUPS). Couns Psychoter Res 2010; 4: 135–56.
32. Sattel H, Lahmann C, Gündel H, Guthrie E, Kruse J, Noll-Hussong M, et al. Brief psychodynamic interpersonal psychotherapy for patients with multisomatiform disorder: randomized controlled trial. Br J Psychiatry 2012; 200: 60–7.
33. Speckens AEM, van Hemert AM, Spinroven P, Hawton KE, Bolk JH, Rooijmans GM. Cognitive behavioural therapy for medically unexplained physical symptoms: a randomised controlled trial. BMJ 1995; 313: 1328–32.
34. McWhinnie I, Epstein R, Freeman T. Rethinking somatization. Ann Intern Med 1997; 126: 747–50.
35. Commissioning Support for London. Medically Unexplained Symptoms: MUS Whole System Approach. London Health Programmes, 2010 (http://www.londonhp.nhs.uk/services/medically-unexplained-symptoms).
36. van der Feitz-Cornelis CM, Hoedeman R, Keuter EI, Swinkels JA. Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. J Psychosom Res 2012; 72: 168–9.